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Summary: We evaluated a new immunoluminometric technique (ILMA) for the measurement of the cancer
antigens, CA 19-9 and CA 125 in serum. A satisfactory reproducibility was found, coefficients of variation
ranging from 4.2 to 7.3% in within-run and between-run assays. The linearity of tests was maintained over
a wide concentration range. Mean analytical recovery was 94% for CA 19-9 and 98% for CA 125. A significant
agreement between results obtained by immunoradiometric assays and evaluated methods was found both
for CA 125 (ILMA = 0.917 IRMA -h 1.048; r = 0.966; n = 98) and CA 19-9 (ILMA = 1.156 IRMA + 0.996;
r = 0.995; n - 100).
Introduction
Cancer antigens (CA) 19-9 and 125 are tumour-as-
sociated antigens, which can be detected by mono-
clonal antibodies. The clinical value of serum CA 19-
9 as a tumour marker of gastrointestinal carcinomas,
and that of CA 125 in ovarian carcinomas has been
proved (1,2).
Until now CA 125 and CA 19-9 have been measured
by immunoradiometric assays (IRMA). All these as-
says suffered the well-known disadvantages of 125I-
labelled tracers: contact with radioactive material and
short-life of the tracer, and its instability due to ra-
diolytic damage to the labelled protein.
The aim of the present work was:
a) to evaluate the analytical efficiency of a new im-
munoluminometric (ILMA) technique for the deter-
minations of CA 19-9 and CA 125 in serum;
b) to compare the results obtained in cancer patients
by IRMA and ILMA methods.
Materials and Methods
A total of 200 subjects were included in this study: 32 were
control subjects (21 males, eleven females, aged 19 — 59 years).
Twenty-eight patients were affected by pancreatic cancer of
duct cell origin (20 males, eight females, aged 43 — 71 years).
Twenty six had chronic pancreatitis (23 males, three females,
aged 29 — 65 years). The diagnosis was based on the clinical
picture and on the positive results of at least two of the follow-
ing examinations: plain abdomen x-ray for pancreatic calcifi-
cation, pancreatic ultrasonography, endoscopic retrograde pan-
creatography, computerized axial tomography. Thirty-seven (27
males, ten females, aged 31—68 years) presented extra-pancre-
atic diseases diagnosed on the results of specific radiological
and/or histological procedures. Thirty-four patients had an
ovarian carcinoma confirmed histologically (27 serous, seven
undifferen tiated).
The other 43 patients were affected by ovarian benign pathology
(27 serous cystoadenomas, five mucinous cystoadenomas, six
benign cystic teratomas, five endometriotic cysts).
The new immunoluminometric assays (LIA-mat, reagents by
Byk-Sangtec, Milan) employed the original antibodies used in
the radioisotopic assays. The OC 125 antibody was obtained
by Bast et al. (3, 4) by immunization of mice with a cell line
derived from an epithelial ovarian carcinoma; the OC 19-9 was
produced by Koprowski et al. by immunization of Balb/c mice
with a cell line derived from a colorectal tumour (5, 6). The
same respective antibodies were used for the coating of the
inner surface of polystyrene tubes, and (after labelling with the
isoluminol derivative, amino-butyl isoluminol (ABEI)) as the
luminescent tracer. The luminescence reaction is initiated by
addition of alkaline hydrogen peroxide and microperoxidase
MP 11, resulting in the burstlike emission of light (Xmax = 425
nm) within a few seconds.
The light signal is directly proportional to the concentration of
tumour markers in standards or samples. The light-producing
reaction and the light-measuring procedure are fully automated
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(Berthold Auto CliniLumat LB952, D-7547 Wildbad, F. R. Ger-
many). The precision studies were performed on patient sera
with different concentration (low and high) of cancer antigens.
The dilution test was carried out by diluting sera of patients
with high concentration of the antigen with the original diluent.
For comparison studies CA 125 and CA 19-9 were determined
by two immunoradiometric assays (IRMA A, reagents by Cen-
tocor INC, Malvern, USA which employs a bead as a solid
phase; IRMA B, reagents by Byk-Sangtec, Milan, which em-
ploys the same antibodies on a coated tube). The correlation
between different methods for CA 19-9 determination was in-
vestigated in 100 subjects (28 pancreatic cancer, 26 chronic
pancreatitis, 30 extra-pancreatic diseases and 16 controls). For
CA 125 the agreement between different methods was evaluated
in 98 subjects (43 ovarian benign pathology, 34 ovarian carci-
noma and 21 controls).
Statistical analysis of data was performed by regression anal-
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Fig. 1. Precision profile of the ILMA assay for CA 19-9 deter-
mination.
Results
The reproducibility of the ILMA methods was eval-
uated both in within-run and between-run assays.
Within-run CVs (n = 20) were 5.9% at 29.3 χ ΙΟ3
U/l and 4.2% at 110.4 χ ΙΟ3 U/l for CA 19-9; and
6.8% at 16.7 χ ΙΟ3 U/l and 4.6% at 272 χ 103 U/l
for CA 125. Between-run CVs (n = 11) were 6.2% at
29.7 χ 103 U/l and 5.1% at 112.1 χ ΙΟ3 U/l for CA
19-9; and 7.3% at 15.4 χ ΙΟ3 U/l and 5.1% at 264.1
χ 103 U/l for CA 125.
The precision profile calculated according to Ekins
demonstrated the wide range of measurement of this
technique (figs. 1 and 2).
Samples were spiked with the antigens and quanti-
tated in order to calculate the analytical recovery.
Mean analytical recovery was 94% (range: 91 —
102%) for CA 19-9 and 98% (range: 96-104%) for
CA 125. The dilutions of sera with high values of CA
19-9 and CA 125 demonstrated that the LIA-mat
technique gives a linear calibration over a wide range
of concentrations (up to 4.5 χ 103 U/l for CA 125
and up to 7.3 χ ΙΟ3 U/l for CA 19-9).
Accuracy was assessed by correlation studies.
CA 125: results were significantly correlated with
those obtained by IRMA A (fig. 3). A significant
correlation was also found between ILMA and IRMA
B results (ILMA = 1.13 IRMA B + 2.057 χ ΙΟ3 U/l;
Syx = 62; r = 0.981, p < 0.001; n = 98).
CA 19-9: a significant correlation between the results
obtained by IRMA A and ILMA was observed (fig.
4), but a positive bias of the ILMA method was
present. However from a clinical point of view, the
diagnostic accuracy (tab. 1) of ILMA was not signif-
icantly different from that of the IRMA method when
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Fig. 2. Precision profile of the ILMA assay for CA 125 deter-
mination.
Good agreement was also found between ILMA and
IRMA B results (ILMA = 1.056 IRMA B + 1.783
χ ΙΟ3 U/l; Syx - 55; r = 0.963, p < 0.001; n - 100).
Discussion
Luminescent labels have proved to be efficient in term
of both specificity and sensitivity and are therefore
suitable for replacing radioisotopes as labels.
Tab. 1. Sensitivity, specificity and diagnostic accuracy of CA











Sensitivity = true positive rate; specificity = true negative rate;
Υ = Youden index = 100 — (false positive rate + false negative
rate)
J. Clin. Chem. Clin. Biochem. / Vol. 28, 1990 / No. 12






25 50 7 5 1 0 0 1 2 5 1 5 0 1 7 5 2 0 0 2 2 5 2 5 0
CA 125 (IRMA A) [103U/1]
20 40 60 80 100 120 140
CA 19-9 (IRMA A) [103U/I]
Fig. 3. CA 125: Correlation between ILMA and IRMA A Fig. 4. CA 19-9: Correlation between ILMA and IRMA A
assays (ILMA = 0.917 IRMA + 1.048 χ ΙΟ3 U/l; Syx assays (ILMA =1.156 IRMA + 0.996 χ l O3 U/l; S^
= 25.0; r = 0.966; n = 98). = 27.2; r = 0.995; n = 100).
The evaluated methods demonstrated good reproduc-
ibility both in within and between-run assays. Good
analytical recovery and linearity were also observed.
The comparison between the evaluated methods and
immunoradiometric assays demonstrated a significant
correlation. Moreover, good agreement between
IRMA and ILMA results was also found from a
clinical point of view.
In conclusion, the evaluated technique seems to be
precise, accurate, well correlated with IRMA and
therefore suitable for routine determination of tumour
markers in clinical practice.
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